Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1368-1377

  Maresca, Giulio ^b   Di Blasio, Anna ^b   Marchioli, Roberto ^b   Di Minno, Giovanni ^a  

^a Clinica e Sperimentale   (Italy)

^b NONE

Author keywords

Fibrinogen; Meta analysis; Myocardial ischemia; Risk factor; Stroke

Indexed keywords

FIBRINOGEN;

CARDIOVASCULAR RISK; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; STATISTICAL ANALYSIS; STROKE;

EID: 0033022434     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1368     Document Type: Review

References (81)

1. Munro JM, Costran RS. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest. 1988;58:249-261.
2. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
3. Ross R. The pathogenesis of atherosclerosis. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia: Saunders; 1997:1105-1125.
4. Henschen A, McDonagh J. Fibrinogen, fibrin and factor XIII. In: Zwaal RFA, Hemker HC, eds. Blood Coagulation. Amsterdam: Elsevier Science Pub Co; 1986;171-241.
5. Atherosclerosis Risk in Community Study. Operation Manual No. 9: Hemost Determinations. Bethesda, MD: National Heart, Lung, and Blood Institute; April 28, 1987. Version 1.0.
6. Bini A, Kudrik BJ. Fibrin and its derivatives in the normal and disease vessel wall. In: Plasminogen activation in fibrinolysis, in tissue remodeling and in development. Ann N Y Acad Sci. 1992;667:112-126.
7. Constantinides P. Cause of thrombosis in human atherosclerotic arteries. Ann J Cardiol. 1990;66:37G-40G.
8. Smith EL, Thompson WD. Fibrin as cofactor in atherogenesis. Thromb Res 1994;73:1-19.
9. Schwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH. Thrombosis and development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemost 1988;14:189-195.
10. Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis. 1990;10:1-7.
11. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985;71:699-708.
12. Davies MJ, Thomas CA. Plaque fissuring: The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
13. Saffitz JE, Schwartz CJ. Coronary atherosclerosis and thrombosis underlying acute myocardial infarction. Cardiol Clin. 1987;5:21-30.
14. Cook NS, Ubben D. Fibrinogen as a major risk factor for cardiovascular disease. Trends Pharmacol Sci. 1990;11:444-451.
15. Ernst E., Resch K. L. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med. 1993;118: 956-963.
16. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
17. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: A Statement for health professionals. Circulation. 1991; 83:356-362.
18. Pyorala K, De Baker G, Graham I, Poole-Wilson P, Wood D on behalf of the Task Force: Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
19. th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 1996;27:957-1047.
20. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
21. Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Iameson JD, Mellows S, Miller GJ, North WRS, Striling Y, Thompson SG. Haemostatic function and ischemic heart disease: The Northwick park heart study. Lancet. 1986;I:533-537.
22. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: The Framingham study. JAMA. 1987;258: 1183-1186.
23. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
24. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL Cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Europ J Clin Invest. 1994;24:444-453.
25. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: Scottish Heart Health Study. Eur Heart J. 1998;19:55-62.
26. Sweetnam PM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA, Elwood PC. Fibrinogen viscosity and the ten year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies. Eur Heart J. 1996; 17:1814-1820.
27. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102-1108.
28. Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
29. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo J, for the European Concerted Action on Thrombosis, and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
30. Thompson SG, Calori G, Thomson JM, Haverkate F, Duckert F. The Impact of Sequential quality assessment exercises on laboratory performance: The Multicentre ECAT Angina Pectoris Study. Report from the European Concerted Action on Thrombosis, and Disabilities (ECAT). Thromb Haemost. 1991;65:149-152.
31. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U, for the Benzafibrate Infarction Prevention (BIP) Study Group. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol. 1996;16:351-356.
32. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997;96:4204-4210.
33. Lee A. J., Lowe GDO, Woodward M., Tunstall-Pedoe H. Fibrinogen in relation to history of prevalent hypertension, diabetes, stroke, intermittent claudicatio, coronary heart disease and family history: The Scottish Heart Health Study. Br Heart J. 1993;69:338-342.
34. Salomaa V, Rasi V, Pekkanen J, Vahtera E, Jauhiainen M, Vartiainen E, Myllyla G, Ehnholm C. Haemostatic factors and prevalent coronary heart disease: The FINRISK haemostasis study. Eur Heart J. 1994;15: 1293-1299.
35. Levenson J, Giral P, Raziavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995;15:1263-1268.
36. Sharp DS, Abbott RD, Burchfiel CM, Rodriguez BL, Tracy RP, Yano K, Curb D. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscler Thromb Vasc Biol. 1996;16: 262-268.
37. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, Morrison CE. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey II. Relationships to cardiovascular disease. Br J Haematol. 1997;97:785-797.
38. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischemic attacks and minor ischemic strokes. BMJ. 1991;303:605-609.
39. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371-375.
40. Wu KK, Folsom AR, Heiss G, Davis CE, Conlan MG, Barnes R, for the ARIC Study Investigators. Association of coagulation factors and inhibitors with carotid Artery Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1992;2:471-480.
41. Koster T, Rosendaal FR, Reitsma PH, van der Valden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis: A case-control study of plasma levels and DNA polymorphisms: the Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994;71:719-722.
42. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analysis of prospective studies. JAMA. 1998;279: 1477-1482.
43. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-effectiveness Analysis. Oxford, England: Oxford University Press; 1994.
44. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;39:1-30.
45. D'Agostino RB, Weintraub M. Meta-analysis: A method for synthesizing research. Clin Pharmacol Ther. 1995;58:605-616.
46. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to Meta-analysis. Am J Epidemiol. 1992;135:1301-1309.
47. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Epidemiol Rev. 1987;9:1-30. International Journal of Technology Assessment in Health Care 1990;6:5-30.
48. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Epidemiol Rev. 1987;9:1-30. International Journal of Technology Assessment in Health Care 1990;6:5-30.
49. Jenicek M. Meta-analysis in medicine where we are and where we want to go. J Clin Epidemiol. 1989;42:34-44.
50. Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stat Med. 1991;9:247-252.
51. Olkin I. A critical look at some popular meta-analytic methods [Invited commentary]. Am J Epidemiol. 1994;140:297-299.
52. Rosner B, Spiegelman D, Willet WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol. 1992;136:1400-1413.
53. Gibaldi M. Meta-analysis: a review of its place in therapeutic decision making. Drugs. 1993;46:805-818.
54. L'Abbè KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
55. Ingram GIC. The determination of plasma fibrinogen by the clot-weight method. Biochem J. 1952;51:583-585.
56. Ellis BC, Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med. 1961;58:477-488.
57. Blomback B, Blomback M. Purification of human bovine fibrinogan. Arkh Kem. 1956;10:415-443.
58. von Clauss A. Gerinnungphysiologische Schnellmethode zur bestimmung des fibrinogen. Acta Haematol. 1957;17:237-246.
59. Brittin GM, Rafinia H, Ravel D, Werner M, Brown B. Evaluationof single radial immunodiffusion for quantitation of plasma fibrinogen. Am J Pathol. 1972;57:89-94.
60. Ernst E, Resch KL, Saradeth T, Maier A, Matrai A. A viscometric method of measuring plasma fibrinogen concentrations. J Clin Pathol. 1992;45: 534-535.
61. Dessert J, Bocquet P, Belleville J, Later R, Quincy C. An automated immunonephelometric method for the quatitiative determination of plasma fibrinogen. Hamostasis. 1973;1:215.
62. Tunstall-Pedoe H, Woodward M, Taverdale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: Cohort study. BMJ. 1997;315:722-729.
63. Marchioli R, Bomba E, Di Pasquale A, Geraci E, Giannuzzi C, Marfisi RM, Pede S, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, a nome dei Ricercatori GISSI-Prevenzione. La carta del rischio post-IMA: Risultati dei primi 18 mesi di follow-up del GISSI-Prevenzione. G Ital Cardiol. 1998;28:416-433.
64. Sweetnam PM, Yarnell WG, Lowe GDO, Baker LA, O'Brein JR, Rumley A, Etherinton MD, Whitehead PJ, Elwood PC. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: The Caerphilly and Speedwell Studies. Br J Haematol. 1998;100:552-558.
65. Fey GH, Fuller GM. Regulation of the acute phase gene expression by inflammatory mediators. Mol Biol Med. 1987;4:323-328.
66. Hassan J, Chelucci C, Peschle C, Sorrentino V. Transforming growth factor b (TGF-b) inhibits expression of fibrinogen and factor VII in a hepatoma cell line. Thromb Haemost. 1992;67:478-483.
67. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the ECAT Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349: 462-466.
68. Maseri A. Inflammation, atherosclerosis, and ischemic events: Exploring the hidden side of the moon. N Engl J Med. 1997;336:1014-1016.
69. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
70. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the b fibrinogen gene is associated with plasma fibrinogen levels in smokers and in non-smokers. Thromb Haemost. 1991;65:487-490.
71. Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet. 1992; 339:693-696.
72. Connor JM, Fowkers FGR, Wood J, Smith FB, Donnan PT, Lowe GDO. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet. 1992;29:480-482.
73. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the b-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: The ECTIM study. Anterioscler Thromb. 1993;13:886-891.
74. de Maat MPM, de Knijff P, Green FR, Thomas AE, Jespersen J, Kluft C. Gender-related association between b-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit. Arterioscler Thromb Vasc Biol. 1995;15:856-860.
75. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou JP, Scarabin PY, Bara L, Green F, Cambien F. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM study. Circulation. 1996;93:440-449.
76. Margaglione M, Cappucci G, Colaizzo D, Pirro L, Vecchione G, Grandone E, Di Minno G. Fibrinogen plasma levels in an apparently healthy general population: Relation to environmental and genetic determinants. Thromb Haemost. 1998;80:805-810.
77. Di Minno G, Grandone E, Margaglione M. Clinical relevance of polymorphic markers of arterial thrombosis. Thromb Haemost. 1997;78: 462-466.
78. Bernardi F, Arcieri P, Bertina RM, Chiarotti F, Corral J, Pinotti M, Prydz H, Samama M, Sanset PM, Strom R, Vincente Garcia V, Mariani G. Contribution of factor VII genotype to activated FVII levels: Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol. 1997;17:2548-2553.
79. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79-85.
80. Ballestein L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, Factor VIII and fibrinogen in an industrial population: I Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using and menopause. Thromb Haemost. 1985;54: 475-479.
81. Fishman D, Foulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo D. The effect of novel polymorphisms in the Interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102: 1369-1376.